4.7 Article

Metabolic Disorders in Patients with Chronic Hepatitis B Virus Infection: Coffee as a Panacea? (ANRS CO22 Hepather Cohort)

期刊

ANTIOXIDANTS
卷 11, 期 2, 页码 -

出版社

MDPI
DOI: 10.3390/antiox11020379

关键词

coffee; tea; hepatitis B; metabolic syndrome; dyslipidemia; hypertension; polyphenol

资金

  1. INSERM-ANRS MIE (France REcherche Nord&sud Sida-vih Hepatites|Maladies Infectieuses Emergentes)
  2. ANR Equipex and Cohort (Agence Nationale de la Recherche)
  3. DGS (Direction Generale de la Sante)
  4. MSD
  5. Janssen
  6. Gilead
  7. Abbvie
  8. BMS
  9. Roche

向作者/读者索取更多资源

A study on HBV-infected individuals found that consuming >= 3 cups of coffee per day was associated with a higher risk of dyslipidemia and a lower risk of hypertension. There was no significant association with diabetes. Further research is needed to determine whether these metabolic benefits translate into reduced mortality risk for patients.
People living with chronic hepatitis B virus (HBV) infection are at high risk of liver disease progression, which is positively associated with metabolic disorders, but inversely associated with dyslipidemia. Diet, including dietary antioxidants, is a lever of metabolic disorder management. In particular, elevated coffee consumption is associated with different metabolic outcomes in the general population. We aimed to test whether such associations occur in HBV-infected people. Based on cross-sectional data from the ANRS CO22 Hepather cohort, we performed logistic regression models with (i) dyslipidemia, (ii) hypertension, and (iii) diabetes as outcomes, and with demographic, clinical, and socio-behavioral (including coffee consumption) data as explanatory variables. Among 4746 HBV-infected patients, drinking >= 3 cups of coffee per day was associated with a higher risk of dyslipidemia (adjusted odds ratio [95% confidence interval] 1.49 [1.10-2.00], p = 0.009) and a lower risk of hypertension (0.64 [0.50-0.82], p = 0.001). It was not associated with diabetes. Elevated coffee consumption was associated with a higher risk of dyslipidemia and a lower risk of hypertension in HBV-infected patients, two effects expected to be associated with favorable clinical outcomes. Further studies should test whether such metabolic benefits translate into reduced mortality risk in this population.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据